tbuckley/cabot-search huggingface dataset:
Prosthetic Eye Care – The Current State of the Art
Authors: Alexander C Rokohl, Keith R Pine, Nicola S Pine, Erik Gordon, Janice Yeoman, Jelmer S Remmers, Dyonne T Hartong, Ludwig M Heindl
Journal: Progress in Retinal and Eye Research (2025)

After eye loss, a fast supply with a visually appealing prosthetic eye is not just a cosmetic solution, it is the key factor for a successful social, occupational, and psychological rehabilitation. For a long time, prosthetic eye care was based on acquired experiences, and there was a significant lack of systematic studies and peer-reviewed literature on this subject. However, in recent decades, research in the field of ocular prosthetics has been driven forward by ophthalmologists, ocularists, optometrists, ophthalmoplastic surgeons, and psychologists. Many essential findings have been made for improving the care of anophthalmic patients. In this extensive review, the current state of the art regarding prosthetic eye care based on the newest scientific findings is summarized. The broad focus includes important historical aspects in ocular prosthetics, in particular the historical development that led to ocularistic care with different prosthetic materials - cryolite glass and polymethyl methacrylate. Furthermore, epidemiology and etiology of eye loss, surgical techniques of eye removal as well as types and production of prosthetic eyes are set out. Important topics with new insights include psychological issues such as living with a prosthetic eye, treatment of children with anophthalmia and microphthalmia, as well as evidence-based prosthetic eye maintenance and handling. In addition, anophthalmic socket complications and associated treatment options with a focus on the common dry anophthalmic socket and post-enucleation socket syndromes were described in detail. Finally, we will speculate how the field of prosthetic eye care will develop in the future.
Parabacteroides distasonis promotes liver regeneration by increasing β-hydroxybutyric acid (BHB) production and BHB-driven STAT3 signals
Authors: Manlan Guo, Xiaowen Jiang, Hui Ouyang, Xianglong Zhang, Shuaishuai Zhang, Peng Wang, Guofang Bi, Ting Wu, Wenhong Zhou, Fengting Liang, Xiao Yang, Shicheng Fan, Jian-Hong Fang, Peng Chen, Huichang Bi
Journal: Acta Pharmaceutica Sinica B (2025)

The liver regenerative capacity is crucial for patients with end-stage liver disease following partial hepatectomy (PHx). The specific bacteria and mechanisms regulating liver regeneration post-PHx remain unclear. This study demonstrated dynamic changes in the abundance of Parabacteroides distasonis (P. distasonis) post-PHx, correlating with hepatocyte proliferation. Treatment with live P. distasonis significantly promoted hepatocyte proliferation and liver regeneration after PHx. Targeted metabolomics revealed a significant positive correlation between P. distasonis and β-hydroxybutyric acid (BHB), as well as hyodeoxycholic acid and 3-hydroxyphenylacetic acid in the gut after PHx. Notably, treatment with BHB, but not hyodeoxycholic acid or 3-hydroxyphenylacetic acid, significantly promoted hepatocyte proliferation and liver regeneration in mice after PHx. Moreover, STAT3 inhibitor Stattic attenuated the promotive effects of BHB on cell proliferation and liver regeneration both in vitro and in vivo. Mechanistically, P. distasonis upregulated the expression of fatty acid oxidation-related proteins, and increased BHB levels in the liver, and then BHB activated the STAT3 signaling pathway to promote liver regeneration. This study, for the first time, identifies the involvement of P. distasonis and its associated metabolite BHB in promoting liver regeneration after PHx, providing new insights for considering P. distasonis and BHB as potential strategies for promoting hepatic regeneration.
Transmission of autochthonous Aedes-borne arboviruses and related public health challenges in Europe 2007–2023: a systematic review and secondary analysis
Authors: Paolo Cattaneo, Elena Salvador, Mattia Manica, Luisa Barzon, Concetta Castilletti, Francesco Di Gennaro, Ralph Huits, Stefano Merler, Piero Poletti, Flavia Riccardo, Annalisa Saracino, Francesco Segala, Lorenzo Zammarchi, Dora Buonfrate, Federico Gobbi
Journal: The Lancet Regional Health - Europe (2025)

Local transmission of dengue, chikungunya, and Zika infection is an emerging public health threat in Europe. Monitoring the epidemiological trends can help define the intervention strategy. The aim of this work was to analyse epidemiological characteristics of autochthonous transmission of Aedes-borne arboviruses in Europe. A systematic review of the literature published from January 1, 2007, to January 31, 2024, reporting autochthonous cases of dengue, chikungunya, and Zika detected in Europe was performed. We searched MEDLINE, EMBASE, and the ECDC reports. Descriptive statistics and a secondary analysis were used to summarize the epidemiological characteristics of local transmission events (LTEs), explore potential temporal trends and identify relevant associations between epidemiological variables. Time intervals between key events were analysed to identify potential delays in LTE identification and intervention. A total of 59 studies were included, describing 56 LTEs. The frequency of LTEs increased over time, with an average of 1.25 (95% CI: 1.17-1.35) times increment every year. While the highest number of dengue LTEs was reported in France (N = 37), Italy faced the largest number of cases detected in an LTE (N = 41). Considering all the arboviral LTEs, the median time between the symptom onset of the primary case and the diagnosis of the index case ("outbreak detection") was 35.5 days (range 23.0-76.0). Only for chikungunya, higher delays correlated with higher cumulative number of cases detected per LTE, though this may be biased due to the low sample size. We have observed a gradual increase of Aedes-borne arboviral LTEs in Europe over time, and a considerable delay in outbreak detection. Improving the timeliness of LTE identification is essential. This work was partly funded by the Italian Ministry of Health (Ricerca corrente) and by the European Union (Next Generation EU, Missione 4 Componente 1 CUP H93C22000640007).
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial
Authors: Maria Domenica Cappellini, Vip Viprakasit, Pencho Georgiev, Thomas D Coates, Raffaella Origa, Abderrahim Khelif, Hong-Keng Liew, Adisak Tantiworawit, Lee-Ping Chew, Abdalla Khalil, P Joy Ho, Kevin H M Kuo, Natalia Holot, Martina Perin, Ana Carolina Giuseppi, Wen-Ling Kuo, Yinzhi Lai, Loyse Felber Medlin, Luciana Moro Bueno, Antonis Kattamis, Ali T Taher
Journal: The Lancet Haematology (2025)
POS0957 EFFECT OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PSA) AND ENTHESITIS AT BASELINE: RESULTS FROM A PHASE 2 TRIAL
Authors: P.J. Mease, S. Dahan, T. Lehman, R. Koti, M.J. Colombo, M. Nowak, A. Deodhar
Journal: Annals of the Rheumatic Diseases (2024)
FRI0464B EFFECT OF FILGOTINIB ON PATIENT-REPORTED OUTCOMES IN ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY
Authors: Laura C Coates, Philip J Mease, Dafna D Gladman, Filip van den Bosch, Chantal Tasset, Luc Meuleners, Robin Besuyen, Jingjing Gao, Mona Trivedi, Thijs Hendrikx, Philip Helliwell
Journal: Annals of the Rheumatic Diseases (2019)
POS1086 ASSOCIATION OF SOCIAL ISOLATION AND LONELINESS WITH MORTALITY IN INDIVIDUALS WITH OSTEOARTHRITIS: AN ANALYSIS OF THE UK BIOBANK COHORT
Authors: M. Zeng, T. Fan, W. Wang, S. Liu, H. Zhang, H. Yang, H. Cen, Q. Yang, G. Ruan, Y. Zhang, Z. Wang, C. Ding, Z. Zhu
Journal: Annals of the Rheumatic Diseases (2024)
POS1235 DELINEATION OF FIBROBLAST-LIKE SYNOVIOCYTE-MEDIATED IMMUNE RESPONSES IN THE PATHOGENESIS OF RHEUMATOID ARTHRITIS
Authors: E. Neofotistou Themeli, P. Goutakoli, E. Sevdali, M. Semitekolou, G.K. Bertsias, P. Verginis, P. Sidiropoulos
Journal: Annals of the Rheumatic Diseases (2024)
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Authors: Victoria Konzett, Josef S Smolen, Peter Nash, Daniel Aletaha, Kevin Winthrop, Thomas Dörner, Roy Fleischmann, Yoshiya Tanaka, Jette Primdahl, Xenofon Baraliakos, Iain B McInnes, Michael Trauner, Naveed Sattar, Maarten de Wit, Jan W Schoones, Andreas Kerschbaumer
Journal: Annals of the Rheumatic Diseases (2025)

This systematic literature review (SLR) on efficacy outcomes was performed to inform the 2024 update of the expert consensus statement on the treatment of immune-mediated inflammatory diseases (IMIDs) with Janus kinase inhibitors (JAKi). An update of the 2019 SLR was performed in MEDLINE, Embase, and the Cochrane Library. For efficacy, randomised, placebo (PLC)- or active-controlled trials on all JAKi investigated in IMIDs, as well as cohort and claims data for conditions where such studies were not available, were included. In total, 10,556 records were screened, and 182 articles were included in the final analysis, investigating 21 JAKi in 51 IMIDs. Forty-three phase 2 and 59 phase 3 trials as well as 9 strategic trials and 72 pilot or cohort studies and case series were considered. JAKi demonstrated efficacy both in PLC-controlled trials as well as in head-to-head comparisons against active comparators, with 93 of 102 randomised controlled trials (RCTs) meeting their primary endpoints. Since 2019, 8 JAKi have received approval by the Federal Drug Agency and the European Medicine Agency for treatment of 11 IMIDs; of these, for 2, no approved disease-modifying antirheumatic drug (DMARD) therapy had previously been available. JAKi are effective for treating IMIDs, and various compounds have recently been approved. The impact of Janus kinase (JAK) selectivity for distinct JAK-STAT pathways needs further investigation, and few data are also available on sustained disease control upon tapering or withdrawal or on the optimal strategic placement of JAKi in international treatment algorithms.
Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma
Authors: Julia Schiantarelli, Mouadh Benamar, Jihye Park, Haley E. Sax, Giacomo Oliveira, Alice Bosma-Moody, Katie M. Campbell, David Liu, Douglas B. Johnson, Scott Rodig, Catherine J. Wu, F. Stephen Hodi, Antoni Ribas, Eliezer Van Allen, Rizwan Haq
Journal: Cancer Cell (2025)

Highlights•Somatic mutations leading to immunotherapy resistance are poorly characterized•Resistance-associated genomic mutations in SEC24C/D were observed in patients•SEC24 mutations exhibited diminished STING signaling and innate immune signaling•SEC24-mutant cells exhibited lower antigen presentation and activation of T cellsSummaryAlthough some patients with metastatic melanoma experience durable responses to immune checkpoint inhibitors (ICIs), most exhibit intrinsic or acquired resistance to these therapies. Here, we compare somatic genomic profiles from matched pre-treatment and post-resistance tumor biopsies in patients (n = 25) with metastatic melanoma who exhibited heterogeneous ICI responses to nominate additional mediators of acquired resistance. We find that several acquired resistance tumors exhibit defects in B2M or JAK1/2, consistent with prior findings. We also discover resistance-associated mutations in SEC24C and SEC24D in 3 patients. SEC24 has an essential role in the trafficking of the dsDNA sensor STING and has been linked to interferonopathies. Melanoma cells engineered to express the SEC24C mutations observed in patients exhibit diminished STING signaling, including decreased type I interferon production, antigen presentation, and a reduced capacity to activate cytotoxic T cells. This study nominates a role for aberrant STING trafficking in acquired resistance to ICIs.Graphical abstract
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Authors: Victoria Konzett, Josef S Smolen, Peter Nash, Kevin Winthrop, Daniel Aletaha, Thomas Dörner, Roy Fleischmann, Yoshiya Tanaka, Jette Primdahl, Xenofon Baraliakos, Iain B McInnes, Michael Trauner, Naveed Sattar, Maarten de Wit, Jan W Schoones, Andreas Kerschbaumer
Journal: Annals of the Rheumatic Diseases (2025)

This systematic literature review (SLR) on safety outcomes was performed to inform the 2024 update of the expert consensus statement on the treatment of immune-mediated inflammatory diseases (IMIDs) with Janus kinase inhibitors (JAKi). An update of the 2019 SLR was performed in MEDLINE, Embase, and the Cochrane Library. For safety, randomised, placebo-controlled or active-controlled trials on all JAKi investigated in IMIDs, long-term extension (LTE) studies, pooled trial data analyses, and cohort and claims studies were included. We screened 13,905 records, of which 209 were finally included. Three safety trials and 13 post hoc analyses, 83 efficacy randomised controlled trials (RCTs) with adequate safety reporting, 56 integrated safety analyses and LTE of RCTs, 20 additional conference abstracts on RCT data, as well as 37 real-world cohort studies were presented to the task force. Safety profiles of JAKi were overall consistent across compounds and indications, but impacts of patient profiles, treatment dosing, and other cofactors like background medications on drug safety could be observed. Furthermore, differential effects of variously selective JAKi on distinct adverse events of special interest (AESI) and laboratory outcomes were discerned. A substantial amount of literature was published on JAKi safety since 2019. A comprehensive overview of these data supports the optimal use of JAKi in patients with IMIDs, by consideration and balance of their benefits as well as risks in every patient.
N-homocysteinylation of β-arrestins biases GPCR signaling and promotes platelet activation
Authors: Lin-Qi Zhang, Chang-Xiao Che, Ya-Qin Du, Lu-lu Han, Jia-le Wang, Chen-Yu Zhang, Shen-Ming Huang, Zhong-Yuan Zheng, Qing-Tao He, Zhao Yang, Long Zhang, Nan Chen, Fan Yang, Ying-Li Jia, Shi-Min Zhao, Demin Zhou, Chu Wang, Xian Wang, Jin-Peng Sun, Lu Tie
Journal: Blood (2025)
17(R)-RESOLVIN D1 PROTECTS AGAINST SICKLE CELL-RELATED INFLAMMATORY CARDIOMYOPATHY IN HUMANIZED MICE
Authors: Enrica Federti, Domenico Mattoscio, Antonio Recchiuti, Alessandro Matte, Maria Monti, Flora Cozzolino, Manuela Iezzi, Martina Ceci, Alessandra Ghigo, Emanuela Tolosano, angela siciliano, Jacopo Ceolan, Veronica Riccardi, Elisa Gremese, Carlo Brugnara, Lucia De Franceschi
Journal: Blood (2025)

Cardiovascular disease has been recognized as the main cause of death in adults with sickle cell disease (SCD). Although the exact mechanism linking SCD to cardiomyopathy remains elusive, a possible role of subclinical acute transient myocardial ischemia during acute sickle-cell-related vaso-occlusive-crisis (VOCs) has been suggested. We approached SCD cardiomyopathy by integrated omics using humanized SS mice exposed to hypoxia/reoxygenation stress (10 hours hypoxia followed by 3 hours reoxygenation, H//R), mimicking acute-VOCs. In SS mice exposed to H/R, a neutrophil-driven cardiac hypertrophic response is initiated by cardiac pro-inflammatory pathways, intersecting proteins and miRNA involved in pro-fibrotic signaling. This response may be facilitated by locally unresolved inflammation. We then examined the effect of 17R-Resolvin-D1 (17R-RvD1), a member of the specialized pro-resolving-lipid mediator superfamily, administration on H/R activated pro-fibrotic and pro-angiogenic pathways. In SS mice, we found that 17R-RvD1 (i) modulates miRNAome; (ii) prevents the activation of NF-kBp65; (iii) protects against the H/R induced activation of both PDGFB-R and TGF-b1/Smad2-3 canonical pathways; (iv) reduces the expression of HIF-dependent pro-angiogenic signaling; (v) decreases the H/R induced pro-apoptotic cell signature. The protective role of 17R-RvD1 against H/R induced maladaptive heart remodeling was supported by the reduction of Gal-3, pro-collagen-C-proteinase-enhancer-1, endothelin-1 expression and perivascular fibrosis in SS mice at 3 days after H/R stress when compared to vehicle-treated SS animals. Collectively our data support the novel role of unresolved inflammation in pathologic heart remodeling in SCD mice in response to H/R stress. Our study provides new evidence for protective effects of 17R-RvD1 against SCD-related cardiovascular disease.
Benchmarking Photon-Counting Computed Tomography Angiography Against Invasive Assessment of Coronary Stenosis
Authors: Rafail A Kotronias, Giovanni L de Maria, Cheng Xie, Sheena Thomas, Kenneth Chan, Leonardo Portolan, Jeremy P Langrish, Jason Walsh, Thomas J Cahill, Andrew J Lucking, Jonathan Denton, Robyn Farrall, Caroline Taylor, Nikant Sabharwal, David A Holdsworth, Thomas Halborg, Stefan Neubauer, Adrian P Banning, Keith M Channon, Charalambos Antoniades
Journal: JACC. Cardiovascular imaging (2025)

Clinical guidelines do not recommend coronary computed tomographic angiography (CTA) in elderly patients or in the presence of heavy coronary calcification. Photon-counting coronary computed tomographic angiography (PCCTA) introduces ultrahigh in-plane resolution and multienergy imaging, but the ability of this technology to overcome these limitations is unclear. The authors evaluate the ability of PCCTA to quantitatively assess coronary luminal stenosis in the presence and absence of calcification, comparing both the ultrahigh-resolution (UHR)-PCCTA and the multienergy standard-resolution (SR)-PCCTA with the criterion-standard 3-dimensional invasive quantitative coronary angiography (3D QCA). The authors included 100 patients who had both PCCTA and invasive coronary angiography (ICA). They comparatively evaluated luminal diameter stenosis with PCCTA and 3D QCA, anatomic disease severity (according to CAD-RADS [Coronary Artery Disease-Reporting and Data System]) and the diagnostic performance of PCCTA in identifying coronary arteries with ≥50% diameter stenosis on 3D QCA requiring invasive hemodynamic severity evaluation and/or revascularization. The authors analyzed 257 vessels and 343 plaques. UHR-PCCTA luminal evaluation relative to 3D QCA was more precise than SR-PCCTA (median difference: 3% [Q1-Q3: 1%-6%] vs 6% [Q1-Q3: 2%-11%]; P < 0.001), particularly in severely calcified arteries (median difference 3% [Q1-Q3: 1%-6%] vs 6% [Q1-Q3: 3%-13%]; P = 0.002). Per-vessel agreement for CAD-RADS between UHR-PCCTA and 3D QCA was near-perfect (κ = 0.90 [Q1-Q3: 0.84-0.95]; P < 0.001), and it was substantial for SR-PCCTA (κ = 0.63 [Q1-Q3: 0.54-0.71]; P < 0.001), especially in severely calcified arteries: κ = 0.90 (Q1-Q3: 0.83-0.97; P < 0.001) and κ = 0.67 (Q1-Q3: 0.56-0.77; P < 0.001), respectively. Per-vessel diagnostic performance of SR- and UHR-PCCTA was excellent: AUC: 0.94 (95% CI: 0.91-0.98; P < 0.001) and 0.99 (95% CI: 0.98-1.00; P < 0.001), respectively. UHR-PCCTA diagnostically outperformed SR-PCCTA: ΔAUC: 0.05 (95% CI: 0.01-0.08; P = 0.01). PCCTA compares favorably with ICA for lumen assessment and anatomic disease severity classification in patients presenting with acute coronary syndrome or patients referred for ICA. UHR-PCCTA luminal evaluation is superior to SR-PCCTA, especially in patients with heavy coronary calcification. UHR-PCCTA has excellent diagnostic performance in identifying coronary arteries with ≥50% luminal stenosis on 3D QCA, outperforming standard-resolution imaging.
Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia
Authors: Jorge J. Llibre-Guerra, M. Victoria Fernandez, Nelly Joseph-Mathurin, Shijia Bian, Kathleen Carter, Yan Li, Andrew J. Aschenbrenner, Cyril Pottier, Wendy Sigurdson, Eric McDade, Brian A. Gordon, Alan E. Renton, Tammie L. S. Benzinger, Laura Ibañez, Nico Barthelemy, Matthew Johnson, Jason Hassenstab, Guoqiao Wang, Alison M. Goate, Dan Western, Ciyang Wang, Diana Hobbs, Alisha Daniels, Celeste Karch, John C. Morris, Carlos Cruchaga, Erik C. B. Johnson, Randall J. Bateman, David Aguillon, Ricardo F. Allegri, Ana Baena, Bryce Baker, Jessica Banks, Nicolas R. Barthélemy, Jamie Bartzel, Randall Bateman, Jacob A. Bechara, Sarah B. Berman, Yamile Bocanegra, William S. Brooks, David M. Cash, Allison Chen, Charles Chen, Jasmeer P. Chhatwal, Patricio Chrem Mendez, Laura Courtney, Alisha J. Daniels, Gregory S. Day, Emma Devenney, Anne M. Fagan, Martin Farlow, Shaney Flores, Nick C. Fox, Erin Franklin, Brian Fulton-Howard, Manu Goyal, Susanne Graber-Sultan, Neill R. Graff-Radford, Emily Gremminger, Cortaiga Hellm, David M. Holtzman, Russ Hornbeck, Edward D. Huey, Laura Ibanez, Takeshi Ikeuchi, Snezana Ikonomovic, Takanobu Ishiguro, Kenji Ishii, Kelley Jackson, Gina Jerome, Mathias Jucker, Celeste M. Karch, Kensaku Kasuga, Sarah Keefe, Deborah Koudelis, Elke Kuder-Buletta, Christian la Fougère, Christoph Laske, Jae-Hong Lee, Allan I. Levey, Johannes Levin, Yudy Milena Leon, Francisco Lopera, Ruijin Lu, Courtney Maa, Jacob Marsh, Mariana Martin, Ralph Martins, Parinaz Massoumzadeh, Colin Masters, Austin McCullough, Nicole McKay, Matthew Minton, Hiroshi Mori, Joyce Nicklaus, Yuzheng Nie, Yoshiki Niimi, James M. Noble, Ulrike Obermueller, Richard J. Perrin, Danielle M. Picarello, Christine Pulizos, Laura Ramirez, Gerald Reischl, John Ringman, Jacqueline Rizzo, Yvonne Rödenbeck, Jee Hoon Roh, Pedro Rosa-Neto, Natalie S. Ryan, Edita Sabaredzovic, Stephen Salloway, Raquel Sanchez-Valle, Peter R. Schofield, Jalen Scott, Michio Senda, Laura Serna, Nicholas T. Seyfried, Ashlee Simmons, Karina Skrbec, Jennifer Smith, Jennifer Stauber, Sarah Stout, Charlene Supnet-Bell, Ezequiel Surace, Reda Timofejavaite, Silvia Vazquez, Andrei Vlassenko, Jonathan Vöglein, Qing Wang, Yong Wang, Chengjie Xiong, Xiong Xu, Jinbin Xu, Angela Ziegemeier, Ellen Ziegemeier
Journal: Nature Medicine (2025)
Contribution of Post-TB Sequelae to Life-Years Lost from TB Disease in the United States, 2015-2019
Authors: Nicolas A. Menzies, Suzanne M Marks, Yuli L Hsieh, Nicole A. Swartwood, Garrett R. Beeler Asay, Jacek Skarbinski, C. Robert Horsburgh, Ted Cohen
Journal: American Journal of Respiratory and Critical Care Medicine (2025)

Individuals surviving TB disease may experience chronic sequelae that reduce survival and quality-of-life. These post-TB sequalae are not generally considered in estimates of the health impact of TB disease. To estimate the TB-attributable reductions in life expectancy and quality-adjusted life expectancy for individuals developing TB disease in the United States, including post-TB sequelae. We extracted national surveillance data on individuals diagnosed with TB during 2015-2019, including demographics, vital status at diagnosis, treatment duration, treatment outcome, and co-prevalent conditions. Using a mathematical model we simulated life expectancy and quality-adjusted life-years (QALYs) for the TB cohort, as compared to a no-TB counterfactual (same distribution of age, sex, race/ethnicity, and co-prevalent conditions as the TB cohort but without TB-attributable mortality and disutility). We disaggregated results to report the proportion due to post-TB sequelae, and stratified outcomes by age, sex, and race. Estimated life expectancy after TB diagnosis was 30.3 (95% uncertainty interval: 29.9, 30.7) years for the TB cohort versus 32.3 (31.9, 32.7) without TB, a difference of 2.03 (1.84, 2.21) years and 1.93 (1.69, 2.18) QALYs. Life-years lost were greatest for 65-74-year-olds versus other age groups, for men versus women, and for American Indian or Alaska Native individuals versus persons from other race/ethnicities. Overall, 41% (35, 46) of life-years and 48% (42, 54) of QALYs lost were estimated to result from post-TB sequelae. In the United States, a substantial fraction of the life-years and QALYs lost from TB are attributable to post-TB sequelae. Evidence is needed on approaches to prevent and repair post-TB lung damage, in the context of frequent co-prevalent health conditions.